Kinarus exploring financial and strategic options for KIN001 development

4 November 2022

Shares of Swiss biopharma Kinarus Therapeutics Holding (SIX: KNRS) were down 13% by midday after it confirmed plans to focus on clinical trials of its lead candidate KIN001 in ophthalmic and pulmonary fibrosis indications, and to refocus its capital resources and financing efforts to drive these programs.

After the company discontinued the Phase II KINETIC study of KIN001 in hospitalized COVID-19 patients, Kinarus is now exploring various financial and strategic options to initiate mid-stage clinical development of its lead drug candidate, KIN001, in wet age-related macular degeneration (wAMD) and idiopathic pulmonary fibrosis (IPF).

KIN001 is a patented combination of pamapimod, a highly selective clinical stage small molecule inhibitor of the p38 MAPK signaling pathway, and pioglitazone, a marketed drug for the treatment of type 2 diabetes.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK